Long-Term Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 196-Week Results From the KEEPsAKE 2 Trial. J of Skin [Internet]. 2024 Nov. 18 [cited 2025 May 19];8(6):s446. Available from: https://skin.dermsquared.com/skin/article/view/3083